Please login or create an account. If you do not have access to this content, you will be shown a 30 second preview and licensing options.
- Presentation
New Treatments in the Pipeline for Pemphigoid
Description
In a presentation on new treatments for bullous pemphigoid, various promising therapeutic strategies targeting specific immune mechanisms were discussed. Bullous pemphigoid is an autoimmune disorder characterized by the formation of autoantibodies that lead to severe skin and mucous membrane damage, particularly in elderly patients who often face treatment challenges due to comorbidities. Current treatments primarily involve systemic steroids, which can adversely affect patient quality of life. New treatment targets include modulation of B cells, IgE, cytokines such as interleukins 5, 13, and 17, as well as complement factors. Notably, drugs like rituximab are recognized for specific cases, while newer agents like Evcardigimov show promise in clinical trials. Dupilumab has demonstrated efficacy by promoting quicker blister resolution with lower immunosuppressive risks. Other investigational strategies involve blocking pathways mediated by interleukin 31 and the application of Janus kinase inhibitors, with some combinations of biological agents also evidencing synergistic effects. The ideal treatment strategy suggested is combined targeted therapy alongside minimal systemic steroid use, emphasizing the need for ongoing research and clinical trials to optimize management of this challenging condition.
View moreConclusions
- Bullous pemphigoid is an autoimmune disorder with significant treatment challenges, particularly for elderly patients with comorbidities.
- Current treatments primarily rely on systemic steroids, which can lead to adverse effects and decreased quality of life.
- New treatment targets have emerged, focusing on specific cytokines and pathways involved in the disease process of bullous pemphigoid.
- Rituximab has limited efficacy for bullous pemphigoid but can be considered for severe or refractory cases.
- FcRn inhibition shows promise as a novel therapeutic strategy for reducing pathogenic autoantibodies.
- Omalizumab appears to be an effective option for patients resistant to first-line therapies, with good tolerance and high rates of remission.
- Dupilumab has demonstrated efficacy in achieving faster responses and reducing corticosteroid dependence in bullous pemphigoid patients.
- Current studies are exploring various targets including interleukins (IL-4, IL-5, IL-17, IL-23) and eotaxin-1.
- Combination therapy strategies may enhance treatment effectiveness while minimizing steroid exposure.
- The ideal treatment paradigm may involve targeted therapies with appropriate use of low-dose systemic steroids or combinations of different agents.
- Seyed Jafari SM, et al. Effects of Omalizumab on FceRI and IgE Expression in Lesional Skin of Bullous Pemphigoid. Front. Immunol. 2019.
- Réda Chebani MD1, et al. Omalizumab in the treatment of bullous pemphigoid resistant to first-line therapy: a French national multicentre retrospective study of 100 patients. BJD 2023.
- Aguado Vázquez Á, et al. Efficacy of Omalizumab for the treatment of Bullous Pemphigoid. Clin Exp Dermatol. 2024 Mar 2:llae067. doi: 10.1093/ced/llae067.
- Yuling Shi, et al. Long-term efficacy and safety of dupilumab for severe bullous pemphigoid: A prospective cohort study. International Immunopharmacology 125 (2023) 111157.
- Chakievska L, et al. IL-17A is functionally relevant and a potential therapeutic target in bullous pemphigoid. J Autoimmun 2019; 96: 104-12.
- Kwatra SG, et al. Phase 3 trial of nemolizumab in patients with prurigo nodularis. N Engl J Med. 2023;389:1579-89.
- Xiao Y, et al. Concurrent bullous pemphigoid and psoriasis vulgaris successfully treated with Janus kinase inhibitor. Int Immunopharmacol. 2023;122: 110591.
- Simon Vikár, et al. The Syk inhibitor entospletinib abolishes dermal-epidermal separation in a fully human ex vivo model of bullous pemphigoid. J Invest Dermatol. 2024.
- S. Morteza Seyed Jafari, et al. Case Report: Combination of Omalizumab and Dupilumab for Recalcitrant Bullous Pemphigoid. Frontiers in Immunology. published: 29 January 2021.
- Stephanie T. Le, et al. Rituximab and Omalizumab Combination Therapy for Bullous Pemphigoid. JAMA Dermatol. 2024;160(1):107-109. doi:10.1001/jamadermatol.2023.4508.